A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study by Inoue Takamitsu et al.
A comparison of nephrotoxicity between
patients with a solitary-functioning kidney
and those with bilateral-functioning kidneys
in cisplatin-based chemotherapy for advanced
urothelial carcinoma: a Japanese retrospective
multi-institutional study
著者 Inoue Takamitsu, Miyazaki Jun, Ichioka Daishi,
Narita Shintaro, Kageyama Susumu, Sugimoto
Mikio, Mitsuzuka Koji, Shiraishi Yusuke,
Kinoshita Hidefumi, Wakeda Hironobu, Nomoto
Takeshi, Kikuchi Eiji, Matsui Yoshiyuki, Fujie
Keiko, Habuchi Tomonori, Nishiyama Hiroyuki
journal or
publication title
BMC cancer
volume 18
number 1
page range 290
year 2018-04
権利 (C) The Author(s). 2018 Open Access This
article is distributed under the terms of the
Creative Commons Attribution 4.0 International
License (
http://creativecommons.org/licenses/by/4.0/ ),
which permits unrestricted use, distribution,
and reproduction in any medium, provided you
give appropriate credit to the original
author(s) and the source, provide a link to
the Creative Commons license, and indicate if
changes were made. The Creative Commons Public
Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1
.0/ ) applies to the data made available in
this article, unless otherwise stated.
URL http://hdl.handle.net/2241/00151776
doi: 10.1186/s12885-018-4186-z
Creative Commons : 表示
http://creativecommons.org/licenses/by/3.0/deed.ja
RESEARCH ARTICLE Open Access
A comparison of nephrotoxicity between
patients with a solitary-functioning kidney
and those with bilateral-functioning
kidneys in cisplatin-based chemotherapy
for advanced urothelial carcinoma: a
Japanese retrospective multi-institutional
study
Takamitsu Inoue1, Jun Miyazaki2, Daishi Ichioka2, Shintaro Narita1, Susumu Kageyama3, Mikio Sugimoto4,
Koji Mitsuzuka5, Yusuke Shiraishi6, Hidefumi Kinoshita7, Hironobu Wakeda8, Takeshi Nomoto9, Eiji Kikuchi10,
Yoshiyuki Matsui11, Keiko Fujie12,13, Tomonori Habuchi1 and Hiroyuki Nishiyama2*
Abstract
Background: To compare the prevalence of nephrotoxicity between patients with a solitary-functioning kidney
versus those with bilateral-functioning kidneys during the administration of cisplatin-based chemotherapy for
advanced urothelial carcinoma.
Methods: We retrospectively analyzed 244 advanced urothelial carcinoma patients treated with cisplatin-based
chemotherapy between 2004 and 2010 at 17 institutes in Japan. The 24 h creatinine clearance, Cockcroft–Gault formula,
and estimated glomerular filtration rate equation (eGFR), were compared before all chemotherapies. The urinary tract
function status was determined based on the data of nephroureterectomy, hydronephrosis, and relief of upper urinary
tract obstruction. A total of 244 patients were divided into four groups according to their urinary tract functioning status
and eGFR results, including bilateral-functioning kidneys with pretreatment eGFR ≥60 mL/min/1.73 m2 group (n = 83, 34.
0%); a solitary-functioning kidney with pretreatment eGFR ≥60 mL/min/1.73 m2 group (n = 36, 14.8%); bilateral-
functioning kidneys with pretreatment eGFR < 60 mL/min/1.73 m2 group (n = 45, 18.4%); and a solitary-
functioning kidney with pretreatment eGFR < 60 mL/min/1.73 m2 group (n = 80, 32.8%).
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Results: The prevalence of nephrotoxicity with impaired eGFR of > 10% and 30% from baseline in the post-third-course
of chemotherapy was significantly higher in patients with bilateral-functioning kidneys than in those with a
solitary-functioning kidney, among patients with pretreatment eGFR < 60 mL/min/1.73 m2 (p = 0.023 and p = 0.026).
During all courses of chemotherapy, the prevalence of nephrotoxicity with impaired eGFR of > 20% from baseline were
significantly higher in patients with bilateral-functioning kidneys than those with a solitary-functioning kidney among
patients with pretreatment eGFR < 60 mL/min/1.73 m2 (p = 0.034), whereas no significant difference was observed
among patients with pretreatment eGFR ≥60 mL/min/1.73 m2.
Conclusions: The results suggest that cisplatin-based chemotherapy may have more nephrotoxicity in patients with
bilateral-functioning kidneys than in those with a solitary-functioning kidney.
Keywords: Urothelial carcinoma, Cisplatin, Nephrotoxicity, Nephroureterectomy, Solitary kidney
Background
Cisplatin-based combination chemotherapies have been
the standard regimen for patients with advanced urothe-
lial carcinoma (UC) since the approval of cisplatin in the
United States in 1993 [1]. The standard regimens for pa-
tients with advanced UC are methotrexate, vinblastine,
doxorubicin, and cisplatin (MVAC), or gemcitabine and
cisplatin (GC). The median overall survival of these two
regimens is 13.8 and 14.8 months, respectively [2, 3]. Al-
though cisplatin is a key drug for the treatment of pa-
tients with advanced UC, a significant nephrotoxicity
associated with cisplatin therapy restricts its use to pa-
tients with appropriate kidney function [4].
To estimate the suitability of cisplatin treatment before
the initiation of therapy, the Cockcroft–Gault formula (C-
G), a modification of diet in renal disease (MDRD) for-
mula, and/or a 24 h creatinine clearance test
(24hCCr) have been widely used to estimate a glomerular
filtration rate (GFR) [5]. A patient with a GFR < 60 mL/
min is usually defined as having the chronic renal disease
(CKD) and cisplatin-ineligible [4]. For cisplatin-ineligible
patients, carboplatin-based combination chemotherapies
have been the most favored regimens, using Calvert’s for-
mula to adjust the dose of carboplatin according to the es-
timated GFR. Outcomes for cisplatin-eligible advanced
UC patients treated with carboplatin-based chemother-
apies, such as gemcitabine plus carboplatin, with a median
overall survival of 9.0 months, were poorer than those for
patients treated with cisplatin-based chemotherapies
[6, 7]. However, in cisplatin-ineligible advanced UC pa-
tients, the median overall survival of patients treated with
carboplatin-based combination chemotherapies are re-
ported 7.2-16.3 months [8–11], which is almost similar
(i.e., around 10 months) in those treated with cisplatin-
based chemotherapies, including the reduction of cisplatin
[12, 13] or a split dose of cisplatin regimens [14–16].
Following radical nephroureterectomy, approximately
78–81% of patients with upper tract urothelial carcinoma
(UTUC) are cisplatin-ineligible (with eGFR < 60 mL/min/
1.73 m2) [17, 18]. Therefore, the recommended treatment
for patients with advanced UTUC, listed in the clinical
guidelines (e.g., the 2015 European Association of Urology
Guidelines), is neoadjuvant chemotherapy only, with con-
sideration made for the fact that chemotherapy-related
nephrotoxicity from platinum derivatives may significantly
reduce survival [9, 19]. However, Lene et al. recently
showed that renal cell carcinoma patients with surgically-
induced CKD (CKD-S) have a relatively low risk of pro-
gressive renal function decline, whereas those with
medically-induced CKD (CKD-M) have an increased risk
[20]. In addition, a previous report from Korea showed
that cisplatin-based chemotherapy was safe in the majority
of patients who underwent nephroureterectomy [21]. It is
plausible that the CKD-S patients, who underwent
nephroureterectomy or who have ipsilateral hydrone-
phrosis and an intact solitary-functioning kidney
without medical comorbidities, have some potential
endurance for nephrotoxicity in cisplatin-based chemo-
therapy. However, currently there is an insufficient
amount of data to support recommendations of chemo-
therapy regimens for CKD-S advanced UC patients with
a solitary-functioning kidney [5, 19].
In this study, the prevalence of nephrotoxicity in
cisplatin-based chemotherapy for advanced UC was
retrospectively compared in cisplatin-ineligible patients
with a solitary-functioning kidney versus those with
bilateral-functioning kidneys, using a Japanese multi-
institutional database.
Methods
In this study, we retrospectively evaluated 345 advanced
or unresectable UC patients who underwent systemic
chemotherapy between 2004 and 2010 at 17 institutes in
Japan (CURE study group). Patients who underwent
neo-adjuvant chemotherapy or chemoradiation for blad-
der preservation were excluded from this study. All cases
required pathological confirmation of UC, except for
patients with upper urinary tract cancer, who were in-
stead diagnosed based on positive urinary cytology and
radiological examinations. The concept of the study was
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approved by the internal ethical committees at all of the
17 institutions involved. Informed consent for chemo-
therapies was obtained from all the patients. Informed
consent to participate in the study was not obtained with
an opt-out statement on the website of all of the 17
institutions involved. Follow-up data were acquired in
December 2013. All data were collected from medical
records at each institution and registered by a secretariat
server on the website.
We selected 244 patients, who underwent cisplatin-based
combination regimens as a first-line chemotherapy and had
data on their kidney function status. The cisplatin-based
combination chemotherapies included in this study were
GC (n = 103, 42.2%); MVAC (n = 98, 40.2%); methotrexate,
epirubicin, and cisplatin (MEC) (n = 35, 14.3%); and gemci-
tabine, cisplatin, and docetaxel (GCD) (n = 8, 3.3%). The se-
lection of chemotherapy regimens was based on the
preference of each institute.
The urinary tract function status was evaluated and
defined by the following criteria: 1) a patient who
underwent radical nephroureterectomy was defined
as having a contralateral solitary-functioning kidney;
2) a patient who had hydronephrosis (regardless of
grade) was defined as having an ipsilateral non-
functional kidney; and 3) a patient who underwent a
relief of upper urinary tract obstruction, including
placement of an internal ureteral stent or nephrost-
omy, was defined as having a functional ipsilateral
kidney. Patients without information on The urinary
tract function status were excluded from this study.
The 24hCCr, C-G, and the Japanese estimated GFR
equation, which originated from the MDRD equation
recommended by the Japanese Society of Nephrology
(eGFR) [22], were compared for GFR estimation be-
fore chemotherapies. The criterion of pretreatment
eGFR ≥60 mL/min/1.73 m2 was used to define cis-
platin eligibility.
The decision to reduce the dose was made by the
physician who treated each patient. Only dose reduc-
tions of cisplatin were evaluated in this study; however,
data on skipped doses were included for all agents.
Serum creatinine levels and eGFR, measured during
chemotherapy, were included for the morning of day
one (pre-), the day of the maximum level of creatinine
(max-), and day 22 (post-) until the fourth course. The
data after the fifth course of first-line cisplatin-based
chemotherapy was not evaluated in this study. Investiga-
tors reported the observed data, including the values of
serum creatinine levels, into the website system follow-
ing first-line chemotherapy, retrospectively.
The chi-square test was used to compare the propor-
tions of clinical parameters between patients with the
bilateral and/or the solitary-functioning kidney. A one-
way repeated measures analysis of variance (ANOVA)-
covariance model and Student’s t-test were used to
determine the between-group differences and the
within-group changes over time, respectively. All
statistical analyses were performed using SPSS software,
version 22.0 (IBM Corp., Armonk, NY, USA), and
P-values of < 0.05 were considered significant.
Results
Determination of the urinary tract function status
According to the criteria described above for the urinary
tract function status, regarding nephroureterectomy,
hydronephrosis, and relief of the upper urinary tract
obstruction, 128 (52.5%) and 116 (47.5%) patients were
defined as having bilateral and solitary-functioning kid-
neys, respectively. Nephroureterectomy and relief of
upper urinary tract obstruction, including the placement
of an internal ureteral stent or nephrostomy, was per-
formed in 49 (20.0%) and 60 (24.5%) patients, respect-
ively. Hydronephroses were left untreated prior to the
initiation of chemotherapy in 16 (6.6%) patients. The
urinary tract function status of all the 244 patients is
listed in Table 1.
Comparison of the methods to estimate GFR
The estimated 24hCCr test was performed in 188 (77.0%)
patients before initiation of chemotherapy. Using results
from the 24hCCr test, 19 (22.1%) and 55 (57.9%) patients
were diagnosed as cisplatin-ineligible with bilateral and
solitary-functioning kidneys, respectively, while eGFR re-
sults defined 45 (35.2%) and 80 (69.0%) patients as
cisplatin-ineligible with bilateral and solitary-functioning
kidneys, respectively. The proportion of patients defined
as cisplatin-ineligible was significantly higher when using
eGFR results versus 24hCCr results (p = 0.040). Further-
more, the proportion of cisplatin-ineligible patients who
had a solitary-functioning kidney was significantly higher
than that of patients with bilateral-functioning kidneys,
using both the 24hCCr and the eGFR tests (p < 0.010 and
p < 0.010; Fig. 1a). The 24hCCr and eGFR tests were sig-
nificantly correlated in patients with bilateral and solitary-
functioning kidneys (r2 = 0.351, p < 0.001 and r2 = 0.402,
p < 0.001; Fig. 1b, c, respectively).
A total of 244 patients were divided into four
groups according to their urinary tract functioning
status and eGFR results as listed in Table 1, including
bilateral-functioning kidneys with pretreatment eGFR
≥60 mL/min/1.73 m2 group (n = 83, 34.0%); a solitary-
functioning kidney with pretreatment eGFR ≥60
mL/min/1.73 m2 group (n = 36, 14.8%); bilateral-
functioning kidneys with pretreatment eGFR < 60 mL/
min/1.73 m2 group (n = 45, 18.4%); and a solitary-
functioning kidney with pretreatment eGFR < 60 mL/
min/1.73 m2 group (n = 80, 32.8%).
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Comparisons of the patient comorbidity, chemotherapy
regimen, dose- reduction, and skipped administration
The demographic data of the four groups at the begin-
ning of chemotherapy treatment is listed in Table 2. The
proportion of patients < 70 years of age with a solitary-
functioning kidney was significantly higher than that of
those with bilateral-functioning kidneys, for all patients
and for patients with pretreatment eGFR ≥60 mL/min/
1.73 m2 (p = 0.016 and p = 0.039, respectively). The pro-
portion of patients with a solitary-functioning kidney
who had lung or liver metastasis was significantly higher
than that of patients with bilateral-functioning kidneys with
pretreatment eGFR ≥60 mL/min/1.73 m2 (both p = 0.018).
The proportion of patients with bilateral-functioning kid-
neys and lymph node metastasis was significantly higher
than patients with a solitary-functioning kidney with pre-
treatment eGFR < 60 mL/min/1.73 m2 (p = 0.010; Table 2).
No significant differences were observed in the proportion
of medical comorbidities between bilateral and solitary-
functioning kidney patients with pretreatment eGFR ≥60 or
< 60 mL/min/1.73 m2.
No significant differences were observed in the selec-
tion of chemotherapy regimens between patients with
the bilateral and solitary-functioning kidneys with re-
spect to those pretreatment eGFR ≥60 or < 60 mL/min/
1.73 m2. The proportion of patients whose cisplatin dose
was reduced was significantly higher in patients with
pretreatment eGFR < 60 mL/min/1.73 m2 than in those
with ≥60 mL/min/1.73 m2 (p < 0.001). No significant dif-
ferences were observed during four courses of cisplatin-
based chemotherapy with regards to the patients with
cisplatin dose reduction or skipped administration of
chemotherapy agents between patients with bilateral and
solitary-functioning kidneys with respect to those with
pretreatment eGFR ≥60 or < 60 mL/min/1.73 m2
(Table 3, Additional file 1: Figure S1).
Comparison of nephrotoxicity during cisplatin-based
chemotherapy
In the comparison of nephrotoxicity between the pa-
tients with bilateral- and solitary-functioning kidneys, no
significant differences were observed in the mean eGFR
between both patients with pretreatment eGFR ≥60 and
< 60 mL/min/1.73 m2 (Fig. 2). However, the prevalence
of nephrotoxicity with impaired eGFR of > 10% and 30%
from baseline in the post-third-course of chemotherapy,
with rates significantly higher in patients with bilateral-
functioning kidneys than in those with a solitary-
functioning kidney among patients with pretreatment
eGFR < 60 mL/min/1.73 m2 (p = 0.023 and p = 0.026;
Table 4, Additional file 2: Figure S2). During all courses
of chemotherapy, the prevalence of nephrotoxicity with
Table 1 Determination of the urinary tract functioning status and pretreatment eGFR of the 244 patients who underwent cisplatin-
based chemotherapies
Pretreatment eGFR
≥60 mL/min/1.73m2
Pretreatment eGFR
< 60 mL/min/1.73m2
Bilateral
functioning
kidneys
(n = 83)
Solitary
functioning
kidney
(n = 36)
Bilateral
functioning
kidneys
(n = 45)
Solitary
functioning
kidney
(n = 80)
Bilateral functoinal kidneys status
BC with bilateral intact kidneys 63 (75.9%) – 23 (51.2%) –
BC with an unilateral nephrostomy 4 (4.8%) – 9 (20.0%) –
UTUC without nephroureterectomy or hydronephrosis 11 (13.3%) – 11 (24.4%) –
UTUC with an ipsilateral nephrostomy 2 (2.4%) – 1 (2.2%) –
BC + UTUC without nephroureterectomy or hydronephrosis 3 (3.6%) – 1 (2.2%) –
Solitary functional kidney status
UTUC after nephroureterectomy – 7 (19.4%) – 37 (46.4%)
UTUC without nephroureterectomy with an ipsilateral – 11 (30.5%) – 22 (27.5%)
UTUC in the solitary kidney without hydronephroisis – 1 (2.7%) – 2 (2.5%)
UTUC in the solitary kidney with the ipsilateral nephrostomy – 0 (0.0%) – 1 (1.2%)
BC with an unilateral hydroneohrosis – 7 (19.4%) – 5 (6.2%)
BC with bilateral hydronephroses with unilateral nephrostomy – 2 (5.6%) – 8 (10.0%)
BC with a solitary kidney – 3 (8.4%) – 1 (1.2%)
BC + UTUC after an unilateral nephroureterectomy – 3 (8.4%) – 2 (2.5%)
BC + UTUC with an unilateral hydronephrosis – 2 (5.6%) – 2 (2.5%)
BC bladder cancer, UTUC upper urinary tract urothelial cancer
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impaired eGFR of > 20% from baseline were significantly
higher in patients with bilateral-functioning kidneys than
in those with a solitary-functioning kidney among
patients with pretreatment eGFR < 60 mL/min/1.73 m2
(p = 0.034; Table 4), whereas no significant difference
was observed among patients with pretreatment eGFR
≥60 mL/min/1.73 m2.
In the comparison of nephrotoxicity between patients
with pretreatment eGFR ≥60 and < 60 mL/min/1.73 m2,
the prevalence of impaired eGFR of > 10% from baseline
in the post-first to fourth courses in patients with
pretreatment eGFR ≥60 mL/min/1.73 m2 was signifi-
cantly higher than those in patients with pretreatment
eGFR < 60 mL/min/1.73 m2 (p = 0.015, p = 0.026, p = 0.011,
and p = 0.010, respectively; Table 4). The prevalence of im-
paired eGFR of > 20% from baseline in the post-third and
fourth courses in patients with pretreatment eGFR
≥60 mL/min/1.73 m2 was significantly higher than those in
patients with pretreatment eGFR < 60 mL/min/1.73 m2
(p = 0.015 and p = 0.028; Table 4). Furthermore, the
prevalence of impaired eGFR of > 30% from baseline at
the post-fourth course in patients with pretreatment
eGFR ≥60 mL/min/1.73 m2 was significantly higher
than that of patients with pretreatment eGFR < 60 mL/
min/1.73 m2 (p = 0.012; Table 4). During all courses of
chemotherapy, the prevalence of impaired eGFR of >
10% and 30% from baseline in patients with pretreat-
ment eGFR ≥60 mL/min/1.73 m2 was significantly
higher than those in patients with pretreatment eGFR
< 60 mL/min/1.73 m2 (p < 0.001 and p = 0.036; Table 4).
No patients required hemodialysis.
Discussion
In advanced UTUC patients following nephroureterect-
omy, the proportion of cisplatin-ineligible patients is re-
portedly 78–81%, and there is often a therapeutic
dilemma in the chemotherapy for these patients [17]. In
total, 37 of the 44 (78.7%) patients who underwent
nephroureterectomy in this study were categorized into
the group of eGFR < 60 mL/min/1.73 m2. Although
carboplatin-based combination chemotherapies have
been the most favored regimens in these kinds of pa-
tients, cisplatin-based chemotherapies were selected in
this study at the discretion of individual institutes, likely
because of the evidence of the better outcomes of
cisplatin-based chemotherapies in cisplatin-eligible ad-
vanced UC [6]. However, the nephrotoxicity of cisplatin-
based chemotherapy in patients with an intact solitary
kidney has not been extensively investigated. The
present study is the first retrospective study comparing
a b
c
Fig. 1 Comparison of the GFR estimation between 24 hCCr, C-G CCr, eGFR, and urinary tract function status. a: Proportions of cisplatin-eligible and in-
eligible patients based on the methods used to estimate the GFR. 24hCCr estimation was performed in 188 (77.0%) patients before chemotherapy
treatment. The proportion of cisplatin-ineligible patients based on eGFR results was significantly higher than when using 24hCCr using the threshold
of 60 mL/min (p = 0.040). The proportion of cisplatin-ineligible patients with a solitary-functioning kidney was significantly higher than
those with bilateral-functioning kidneys using both 24hCCr and eGFR tests (p < 0.010 and p < 0.010). b: 24hCCr and eGFR were signifi-
cantly correlated in patients with bilateral-functioning kidneys (r2 = 0.351, p< 0.001). c: 24hCCr and eGFR were significantly correlated in patients with a
solitary-functioning kidney (r2 = 0.402, p< 0.001)
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the nephrotoxicity between bilateral- and solitary-
functioning kidneys in CKD patients during cisplatin-
based chemotherapies.
In the evaluation of the mean value of eGFR in this
study, the kidney function did not deteriorate during
four courses. Moreover, the mean kidney function be-
tween patients with bilateral- and solitary-functioning
kidneys did not significantly differ in both patients with
pretreatment eGFR ≥60 and < 60 mL/min/1.73 m2.
However, there should be a significant bias noted in that
the patients who did not continue the chemotherapy due
to nephrotoxicity were excluded from the next course in
the evaluation of the mean value of eGFR. Therefore, we
focused more on the nephrotoxicity of individual patients;
indeed, the nephrotoxicity was more frequently observed in
patients with bilateral-functioning kidneys than in
those with a solitary-functioning kidney in patients
with pretreatment eGFR < 60 mL/min/1.73 m2. The de-
tails of cisplatin-based chemotherapy were almost not
found to be significantly different between groups based
on the selection of chemotherapy regimen, reduction of
cisplatin dose and/or the requirement to skip administra-
tion of the chemotherapy agents. Although the difference
was slight, our data suggest that kidney function is more
likely to be injured by cisplatin-based chemotherapies in
patients with bilateral-functioning kidneys than in those
with a solitary-functioning kidney.
The reason for our results may be that the
microstructures of the nephrons in CKD-S patients fol-
lowing contralateral nephroureterectomy or hydrone-
phrosis are less deteriorated and more resistant to
chemotherapy than those in CKD-M patients with
bilateral-functioning kidneys. Although the difference
was not significant, comorbidities were more frequently
Table 2 Demographic data of analyzed 244 patients who underwent cisplatin-based chemotherapies
All patients Pretreatment eGFR
≥60 mL/min/1.73m2
Pretreatment eGFR
< 60 mL/min/1.73m2
Pretreatment
eGFR ≥60
mL/min/
1.73m2
(n = 119)
Pretreatment
eGFR < 60
mL/min/
1.73m2
(n = 125)
p Bilateral
functioning
kidneys
(n = 83)
Solitary
functioning
kidney
(n = 36)
p Bilateral
functioning
kidneys
(n = 45)
Solitary
functioning
kidney
(n = 80)
p
Age < 70 78 (65.5%) 63 (50.4%) 0.016 49 (58.9%) 29 (80.5%) 0.039 20 (44.4%) 43 (53.7%) 0.32
≥70 41 (34.4%) 62 (49.6%) 34 (41.1%) 7 (19.5%) 25 (55.6%) 37 (46.3%)
PS 0-1 111 (93.2%) 117 (93.6%) 0.91 77 (92.7%) 34 (94.4%) 0.94 42 (93.3%) 75 (93.8%) 0.083
2-4 8 (6.7%) 8 (6.4%) 6 (7.3%) 2 (5.6%) 3 (6.7%) 5 (6.2%)
Sex Male 86 (72.3%) 87 (69.6%) 0.64 61 (73.5%) 25 (69.4%) 0.65 32 (71.1%) 55 (68.7%) 0.78
Female 33 (27.7%) 38 (30.4%) 22 (26.5%) 11 (30.6%) 13 (28.9%) 25 (31.3%)
Comorbidities yes 15 (12.6%) 17 (14.2%) 0.81 13 (15.7%) 2 (5.6%) 0.12 8 (17.8%) 9 (11.2%) 0.36
no / unknown 104 (87.4%) 108 (86.4%) 70 (84.3%) 34 (94.4%) 37 (82.2%) 71 (88.8%)
DM 3 (2.5%) 4 (3.2%) 2 (2.4%) 1 (2.7%) 2 (4.4%) 2 (2.4%)
Glomerulonephritis 1 (0.8%) 1 (0.8%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 1 (1.2%)
Others 11 (9.2%) 12 (9.6%) 10 (12.1%) 1 (2.7%) 6 (13.3%) 6 (7.5%)
Cancer
location
BC 79 (66.5%) 46 (36.8%) < 0.001 67 (80.7%) 12 (33.3%) < 0.001 32 (71.1%) 14 (17.5%) < 0.001
UTUC 32 (26.8%) 74 (59.2%) 13 (15.7%) 19 (52.8%) 12 (26.7%) 62 (77.5%)
BC + UTUC 8 (6.7%) 5 (4.0%) 3 (3.6%) 5 (13.9%) 1 (2.2%) 4 (5.0%)
Surgery No surgery 85 (71.5%) 73 (58.4%) 0.033 63 (75.9%) 22 (61.1%) < 0.001 38 (84.4%) 35 (43.7%) < 0.001
Cystectomy 25 (21.0%) 14 (11.2%) 20 (24.1%) 5 (13.9%) 7 (15.6%) 7 (8.8%)
Nephroureterectomy 7 (5.8%) 37 (29.6%) 0 (0.0%) 7 (19.4%) 0 (0.0%) 37 (46.3%)
Cystectomy +
nephroureterectomy
2 (1.7%) 1 (0.8%) 0 (0.0%) 2 (5.6%) 0 (0.0%) 1 (1.2%)
Metastatic site Lymph node 77 (64.7%) 68 (54.4%) 0.10 55 (66.2%) 22 (61.1%) 0.58 33 (73.3%) 35 (43.8%) 0.001
Lung 41 (34.5%) 45 (36.0%) 0.80 23 (12.1%) 18 (50.0%) 0.018 16 (35.6%) 29 (36.3%) 0.94
Liver 24 (20.2%) 18 (14.4%) 0.23 12 (14.5%) 12 (33.3%) 0.018 6 (13.3%) 12 (15.0%) 0.79
Bone 22 (18.5%) 17 (13.6%) 0.29 13 (15.7%) 9 (25.0%) 0.23 6 (13.3%) 11 (13.7%) 0.95
Others 28 (23.5%) 32 (25.6%) 0.70 15 (18.1%) 13 (36.1%) 0.033 9 (20.0%) 23 (28.7%) 0.28
BC bladder cancer, UTUC upper urinary tract urothelial cancer
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observed in patients with bilateral-functioning kidneys
than in those with a solitary-functioning kidney. Histor-
ies of diabetes mellitus and cardiovascular disease were
found to be significant risk factors to predict severe
acute kidney injury induced by cisplatin-based chemo-
therapy in a previous evaluation of 1721 cancer patients
[23]. Although the mean body mass index was not sig-
nificantly different between the groups in this series,
there is a possibility that the potential deterioration
of the kidney such as smoking status, hypertension,
or hyperuricemia might be more prevalent in pa-
tients with bilateral-functioning kidneys than in
those with a solitary-functioning kidney.The differ-
ences of these factors were not obvious because of
the retrospective study.
Another finding in this retrospective study was that pa-
tients with impaired kidney function were more frequently
observed in patients with pretreatment eGFR ≥60 than in
< 60 mL/min/1.73 m2, probably because of the frequent
dose reductions in patients with pretreatment eGFR <
60 mL/min/1.73 m2. Moreover, the prevalence of the
nephrotoxicity increased as chemotherapy courses pro-
gressed, during the four courses in patients with pretreat-
ment eGFR ≥60 mL/min/1.73 m2, with an 8.4% reduction
in the dose of cisplatin. However, the prevalence was not
increased in patients with pretreatment eGFR < 60 mL/
min/1.73 m2 with a 33.6% reduction in the dose of cis-
platin. The effectiveness and the safety of cisplatin dose
reduction in patients with pretreatment eGFR < 60 mL/
min/1.73 m2 has not been clearly elucidated because of
Table 3 Comparison of the proportion of the selected chemotherapy regimens, dose-reduction, and skip administration
All patients Cisplatin-eligible
(eGFR ≥60 mL/min/1.73m2)
Cisplatin-ineligible
(eGFR < 60 mL/min/1.73 m2)
Cisplatin-eligible
(n = 119)
Cisplatin-ineligible
(n = 125)
p Bilateral
functioning
kidneys
(n = 83)
Solitary
functioning
kidney
(n = 36)
p Bilateral
functioning
kidneys
(n = 45)
Solitary
functioning
kidney
(n = 80)
p
Chemotherapy GC 48 (40.3%) 55 (44.0%) 0.56 35 (42.2%) 13 (36.2%) 0.530 24 (53.3%) 31 (38.8%) 0.160
MVAC 52 (43.6%) 46 (36.8%) 0.27 37 (44.6%) 15 (41.6%) 0.760 14 (31.1%) 32 (40.0%) 0.110
MEC 16 (13.4%) 19 (15.2%) 0.70 9 (10.8%) 7 (19.4%) 0.210 4 (8.9%) 15 (18.7%) 0.140
Gemcitabine
+ Cisplatin +
Docetaxel
3 (2.5%) 5 (4.0%) 0.51 2 (2.4%) 1 (2.8%) 0.900 3 (6.7%) 2 (2.5%) 0.850
Cisplatin dose reduction
all courses Yes 10 (8.4%) 42 (33.6%) < 0.001 6 (7.2%) 4 (11.1%) 0.480 16 (35.5%) 26 (32.5%) 0.730
1st course Yes 9/119 (7.5%) 48/125 (38.4%) < 0.001 6/83 (7.2%) 3/36 (8.3%) 0.834 16/45 (35.5%) 32/80 (39.9%) 0.623
99-80% 8/119 (6.7%) 15/125 (12.0%) 0.158 5/83 (6.0%) 3/36 (8.3%) 0.644 5/45 (11.1%) 10/80 (12.5%) 0.810
< 80% 1/119 (0.8%) 33/125 (26.4%) < 0.001 1/83 (1.2%) 0/36 (0.0%) 0.508 11/45 (24.4%) 22/80 (27.5%) 0.709
2nd course Yes 8/104 (7.7%) 39/110 (35.3%) < 0.001 5/72 (8.3%) 3/32 (9.3%) 0.667 13/42 (30.8%) 26/68 (38.1%) 0.437
99-80% 7/104 (6.7%) 9/110 (8.1%) 0.686 4/72 (6.9%) 3/32 (9.3%) 0.473 2/42 (4.7%) 7/68 (10.2%) 0.303
< 80% 1/104 (1.0%) 30/110 (27.2%) < 0.001 1/72 (1.4%) 0/32 (0.0%) 0.500 11/42 (26.1%) 19/68 (27.9%) 0.841
3rd course Yes 4/81 (4.9%) 23/82 (28.0%) < 0.001 2/54 (3.8%) 2/27 (7.4%) 0.468 6/24 (24.9%) 17/58 (29.2%) 0.690
99-80% 3/81 (3.7%) 7/82 (8.5%) 0.198 1/54 (1.9%) 2/27 (7.4%) 0.212 1/24 (4.1%) 6/58 (10.3%) 0.362
< 80% 1/81 (1.2%) 16/82 (19.5%) < 0.001 1/54 (1.9%) 0/27 (0.0%) 0.476 5/24 (20.8%) 11/58 (18.9%) 0.846
4th course Yes 2/59 (3.4%) 15/59 (25.4%) < 0.001 0/39 (0.0%) 2/20 (10.0%) 0.044 4/20 (20.0%) 12/39 (30.7%) 0.378
99-80% 2/59 (3.4%) 6/59 (10.2%) 0.142 0/39 (0.0%) 2/20 (10.0%) 0.044 1/20 (5.0%) 5/39 (12.8%) 0.346
< 80% 0/59 (0.0%) 9/59 (15.2%) < 0.001 0/39 (0.0%) 0/20 (0.0%) 1.000 3/20 (15.0%) 7/39 (17.9%) 0.775
Skip
all courses Yes 65 (54.6%) 70 (56.0%) 0.83 49 (59.0%) 16 (44.4%) 0.140 23 (51.1%) 47 (58.8%) 0.400
No 54 (45.3%) 55 (44.0%) 34 (40.9%) 20 (55.6%) 22 (48.9%) 33 (41.2%)
1st course day 8 8 (6.7%) 15 (12.0%) 0.16 7 (8.4%) 1 (2.7%) 0.250 4 (8.9%) 11 (13.7%) 0.420
day 15 54 (45.3%) 54 (43.2%) 0.73 40 (48.1%) 14 (38.9%) 0.340 17 (37.7%) 37 (46.3%) 0.350
day 22 8 (6.7%) 13 (10.4%) 0.30 6 (7.2%) 2 (5.6%) 0.730 4 (4.4%) 9 (11.3%) 0.680
BC bladder cancer, UTUC upper urinary tract urothelial cancer
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the ethical difficulties surrounding conducting such a
prospective study [12, 24]. Although the one-year overall
survival of the patients treated with a reduced dose of cis-
platin-based chemotherapy was significantly lower than
that of those treated with the standard dose in the CURE
study using the same patient series [13], the results of this
study demonstrated the safety of cisplatin dose reduction
for cisplatin-ineligible patients in preventing nephrotoxicity.
Even considering our study results, cisplatin-based
chemotherapy is not always safe and is not recom-
mended for all the CKD-S patients with a solitary-
functioning kidney with pretreatment eGFR < 60 mL/
min/1.73 m2. However, the threshold and method to de-
termine cisplatin-eligibility for patients with marginal
kidney function are still controversial. Previous studies
have shown about two-thirds of discordance in three
methods of GFR estimation [5]. From the current study
results, cisplatin-based chemotherapies could be recom-
mended at least in CKD-S patients with marginal kidney
function, such as around 10% of patients who are
categorized in pretreatment 24hCCr > 60 mL/min, as
well as eGFR < 60 mL/min/1.73 m2, as shown in Fig.
1. For patients with pretreatment eGFR of 50–60 mL/
min/1.73 m2, 15/16 (93.7%) and 23/26 (88.5%)
patients received a standard dose of cisplatin in bilat-
eral- and solitary-functioning kidney patients, respect-
ively. The prevalence of nephrotoxicity by more than
30% impaired kidney function during all courses of
chemotherapy was 2/16 (12.5%) and 3/24 (12.5%),
respectively.
There are several considerable limitations in this
study. First, this study is a retrospective evaluation,
and chemotherapy regimens or dose reductions for
each cisplatin-ineligible patient were carefully selected
under the discretion at each institute before initiation
of the treatments. Patients with lower kidney func-
tion, higher age, and/or lower performance status re-
ceived alternative regimens with or without platinum
agents. In actuality, 90 of the 345 (26.1%) patients
evaluated in the CURE study group, including 70
cisplatin-ineligible patients, did not receive cisplatin-
based chemotherapies and of them, 57 received other
platinum-based combination chemotherapy regimens
consisting of carboplatin or nedaplatin, while 33 received
chemotherapy without platinum agents. Second, only
cisplatin but not methotrexate was considered as the
nephrotoxic agent in this study. Third, the use of a
detailed objective scoring system of medical comorbidities,
such as the Charlson Comorbidity Index, was not evalu-
ated in this study. Lastly, not only patients with nephrour-
eterectomy but also patients who had unilateral
hydronephrosis or who underwent a relief of the upper
urinary tract obstruction were included in the group of
patients with a solitary kidney. As such, variations in func-
tional status of the urinary tract in patients with a solitary
kidney are also a considerable limitation of this study.
Fig. 2 Comparison of the mean eGFR value during cisplatin-based chemotherapies between bilateral and solitary-functioning kidneys, in patients
with eGFR ≥60 and < 60 mL/min/1.73 m2. No significant differences were observed in the mean eGFR between patients with bilateral
and solitary-functioning kidneys
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Conclusions
The results suggest that cisplatin-based chemother-
apies may have more nephrotoxicity in patients with
bilateral-functioning kidneys than in those with a
solitary-functioning kidney. The nephrotoxicity of the
chemotherapy may be of increased concern in CKD-
M patients with bilateral-functioning kidneys than in
CKD-S patients with a solitary-functioning kidney.
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